A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
COSCIENS Biopharma Inc.
CSCIF
$13M
Mkt Cap
$4.98
+0.00%
Item 4. Information on the Company A. History and development of the Company The Company was incorporated on September 12, 1990 under the Canada Business Corporations Act (the “CBCA”) and continues to be governed by the CBCA. Our registered address is located at 222 Bay St., Suite 3000, Toronto, Ontario, Canada M5K 1E7 c/o Norton Rose Fulbright Canada LLP and we operate another office located at 315 Sigma Drive, Summerville, South Carolina 29486; our telephone number is (843) 900-3223 and our website is www.cosciensbio.com/. In May 2004, we changed our name to Aeterna Zentaris Inc. On May 3, 2024, we completed a 4-for-1 share consolidation (reverse stock split) and previously, on July 18, 2022, we completed a 25-for-1 share consolidation and on November 17, 2015, we completed 100-to-1 share consolidation (reverse stock split).
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 9.6M | 9.6M | - | 15M | 5.3M | 550K |
| Net Income | -15M | -15M | -17M | -23M | -8.4M | - |
| EPS | $-5.93 | $-5.93 | $-7.56 | $7.44 | $-182.00 | - |
| Free Cash Flow | -16M | -16M | -18M | 4.9M |
| Metric | 2015 | 2016 | 2020 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 545K | N/A | N/A | 27M | N/A | 550K | 5.3M | 15M | N/A | 9.6M | 9.6M |
| Gross Margin | N/A | N/A | N/A | 92.2% | N/A | N/A | N/A | 58.7% | N/A | 49.3% | 49.3% |
| R&D | 17M | 16M | 11M | 2.9M | 1.8M | N/A | 6.6M | 13M | 14M | 8.3M | 8.3M |
| SG&A | 11M | 7.1M | 8.2M | 8.9M | 6.6M | N/A | 7.3M | 8.2M | 5.5M | 10M | 10M |
| EBIT | -35M | -29M | -23M | 9.8M | -10M | N/A | -8.7M | -24M | -18M | -18M | -18M |
| Op. Margin | -6400.7% | N/A | N/A | 36.6% | N/A | N/A | -164.8% | -162.0% | N/A | -190.7% | -190.7% |
| Net Income | N/A | -25M | -17M | 4.2M | -6.0M | N/A | -8.4M | -23M | -17M | -15M | -15M |
| Net Margin | N/A | N/A | N/A | 15.6% | N/A | N/A | -159.1% | -156.0% | N/A | -159.7% | -159.7% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Returns on Capital | |||||||||||
| ROIC | N/A | N/A | -82.1% | 25.0% | -51.3% | N/A | -25.3% | -99.3% | -73.8% | -89.5% | -41.2% |
| ROE | N/A | N/A | -979.6% | 219.6% | N/A | N/A | -25.3% | -99.3% | -73.8% | -89.5% | -116.3% |
| ROA | N/A | -35655.7% | -75.7% | 17.7% | -26.9% | N/A | -10.4% | -38.6% | -53.8% | -52.1% | -43.7% |
| Cash Flow | |||||||||||
| Op. Cash Flow | -34M | -29M | -23M | 6.8M | -11M | 0 | -8.6M | 5.2M | -17M | -15M | -15M |
| Free Cash Flow | -34M | -29M | -23M | 6.8M | -11M | N/A | -8.6M | 4.9M | -18M | -16M | -16M |
| Owner Earnings | -34M | -29M | -23M | 6.8M | -11M | 0 | -8.7M | 3.8M | -19M | -16M | -16M |
| CapEx | 26K | 66K | 4K | 9K | 0 | 0 | 30K | 304K | 722K | 1.2M | 1.2M |
| Maint. CapEx | 341K | 280K | 94K | 58K | 315K | 0 | 145K | 1.5M | 1.4M | 1.6M | 1.6M |
| Growth CapEx | 0 | 0 | 0 | 0 | N/A | N/A | 0 | 0 | 0 | 0 | 0 |
| D&A | 341K | 280K | 94K | 58K | 315K | 0 | 145K | 1.5M | 1.4M | 1.6M | 1.6M |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | |||||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Stock-Based Comp | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Balance Sheet | |||||||||||
| Net Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -16M |
| Cash & Equiv. | 41M | 22M | 7.8M | 15M | 7.8M | 24M | 65M | 51M | 34M | 16M | 16M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Debt/Equity | N/A | N/A | -8.98 | 12.12 | -9.11 | N/A | 0.51 | 0.85 | 0.89 | 1.66 | 0.00 |
| Interest Coverage | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -165.1 | -132.4 | -141.7 | -141.7 |
| Equity | N/A | N/A | -2.8M | 1.9M | -2.5M | 13M | 53M | 24M | 21M | 13M | 13M |
| Total Assets | 237K | 70K | 22M | 25M | 20M | N/A | 80M | 38M | 24M | 35M | 35M |
| Total Liabilities | N/A | N/A | 25M | 23M | 22M | N/A | 27M | 20M | 19M | 22M | 22M |
| Intangibles | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Retained Earnings | N/A | N/A | -314M | -310M | -317M | N/A | -335M | -352M | -370M | -12M | -12M |
| Working Capital | N/A | N/A | 3.6M | 11M | 5.3M | N/A | 63M | 48M | 32M | 17M | 17M |
| Current Assets | N/A | N/A | 9.4M | 16M | 11M | N/A | 71M | 55M | 36M | 24M | 24M |
| Current Liabilities | N/A | N/A | 5.8M | 5.6M | 5.7M | N/A | 7.8M | 7.0M | 4.5M | 7.2M | 7.2M |
| Per Share Data | |||||||||||
| EPS | -1,814,000.00 | -241.00 | -112.00 | 24.00 | -35.00 | N/A | -182.00 | 7.44 | -7.56 | -5.93 | -5.93 |
| Owner EPS | -207.93 | -282.82 | -153.42 | 38.79 | -9.09 | 0.00 | -189.79 | 4.79 | -23.64 | -6.27 | -6.27 |
| Book Value | N/A | N/A | -18.56 | 10.93 | -2.03 | 272.06 | 1,152.42 | 30.34 | 26.79 | 5.10 | 5.10 |
| Cash Flow/Share | -205.85 | -280.12 | -152.79 | 39.12 | -8.83 | N/A | -186.63 | 6.66 | -21.80 | -5.64 | -5.31 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 0.2M | 0.1M | 0.1M | 0.2M | 1.2M | 0.0M | 0.0M | 0.8M | 0.8M | 2.6M | 2.6M |
| Valuation | |||||||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -0.8 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 1.0 |
| Price/Sales | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 1.3 |
| FCF Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -122.3% |
| Market Cap | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 13M |
| Avg. Price | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.98 |
| Year-End Price | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.98 |
COSCIENS Biopharma Inc. passes 1 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average gross margin is 54.0%.
COSCIENS Biopharma Inc. (CSCIF) has a 5-year average return on invested capital (ROIC) of -72.0%. This is below average and may indicate limited pricing power.
COSCIENS Biopharma Inc. (CSCIF) has a market capitalization of $13M. It is classified as a small-cap stock.
COSCIENS Biopharma Inc. (CSCIF) does not currently pay a regular dividend.
COSCIENS Biopharma Inc. (CSCIF) operates in the Perfumes, Cosmetics & Other Toilet Preparations industry, within the Consumer Defensive sector.
COSCIENS Biopharma Inc. (CSCIF) reported annual revenue of $10 million in its most recent fiscal year, based on SEC EDGAR filings.
COSCIENS Biopharma Inc. (CSCIF) has a net profit margin of -159.7%. The company is currently unprofitable.
COSCIENS Biopharma Inc. (CSCIF) generated $-16 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
| -8.6M |
| - |
| ROIC | -41.2% | -89.5% | -73.8% | -99.3% | -25.3% | - |
|---|
| Gross Margin | 49.3% | 49.3% | - | 58.7% | - | - |
|---|
| Debt/Equity | 0.00 | 1.66 | 0.89 | 0.85 | 0.51 | - |
|---|
| Dividends/Share | $0.00 | - | - | - | - | - |
|---|
| Operating Income | -18M | -18M | -18M | -24M | -8.7M | - |
|---|
| Operating Margin | -190.7% | -190.7% | - | -162.0% | -164.8% | - |
|---|
| ROE | -116.3% | -89.5% | -73.8% | -99.3% | -25.3% | - |
|---|
| Shares Outstanding | 3M | 3M | 1M | 1M | 0M | 0M |
|---|
COSCIENS Biopharma Inc. (CSCIF) has a debt-to-equity ratio of 1.66. This indicates higher leverage, which may increase financial risk.
COSCIENS Biopharma Inc. (CSCIF) reported earnings per share (EPS) of $-5.93 in its most recent fiscal year.
COSCIENS Biopharma Inc. (CSCIF) has a return on equity (ROE) of -89.5%. A negative ROE may indicate losses or negative equity.
COSCIENS Biopharma Inc. (CSCIF) has a 5-year average gross margin of 54.0%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 10 years of financial data for COSCIENS Biopharma Inc. (CSCIF), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
COSCIENS Biopharma Inc. (CSCIF) has a book value per share of $5.10, based on its most recent annual SEC filing.